Clinical Education InitiativeMenu
Search
Home > Courses > The Kidney in HIV Treatment and Prevention: Current Considerations

The Kidney in HIV Treatment and Prevention: Current Considerations

The Kidney in HIV Treatment and Prevention: Current Considerations
The Kidney in HIV Treatment and Prevention: Current Considerations
Play
Sorry, this learning module is not available for mobile devices.
Resource ID: CM408
Original Presentation: 4/12/2016
Web Posting: 7/6/2016
CE Expiration: 04/11/2019
Presenter
  • Christina M. Wyatt, MD
    Associate Professor of Medicine, Department of Nephrology
    Icahn School of Medicine at Mount Sinai, New York, NY
Learning Objectives
At the completion of this educational session, participants will:
  1. Identify HIV-positive adults who are at increased risk of kidney disease.
  2. Understand the risk of nephrotoxicity in adults initiating ART or PrEP.
  3. Describe new and emerging approaches to reduce the risk of ART nephrotoxicity.
Presenter Bio
Christina Wyatt, MD
Christina Wyatt’s research has focused on defining the epidemiology of kidney disease among HIV-infected individuals, including those with comorbid risk factors such as Hepatitis C co-infection and diabetes. She is also the on-site nephrologist for the Mount Sinai Institute for Advanced Medicine, which provides clinical care for nearly 10,000 individuals living with HIV infection. Her research has involved productive collaborations with large HIV cohorts, including the VA Aging Cohort Study, the WIHS, and the INSIGHT clinical trials network. Dr. Wyatt is the PI on an R01 investigating the potential for kidney injury with oral antiretroviral therapy for HIV pre-exposure prophylaxis, and she directs the clinical core of a longstanding P01 investigating the pathogenesis of HIV-associated nephropathy. In addition to original research publications, she has been an invited presenter at international scientific meetings in HIV and nephrology, and an invited contributor to more than twenty reviews and book chapters on HIV-related kidney disease and antiretroviral nephrotoxicity.
Continuing Education Credit

This CME activity was approved for AMA PRA Category 1 Credit™ on April 12, 2016 and will terminate April 11, 2019.

The target audience is all physicians, NPs and PAs involved or interested in HIV education.

This online video and post-activity evaluation are one hour in length.

  • After you complete the video portion of this educational activity there will be a post-activity evaluation and quiz.
  • You must achieve at least 70% correct to receive your CME certificate.
  • If successful, you will be provided instructions to print your CME certificate at the completion of this activity.

Accreditation Statement

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the Medical Society of the State of New York (MSSNY) and the Physicians’ Research Network (PRN). MSSNY is accredited by the ACCME to provide continuing medical education for physicians.

The Medical Society of the State of New York designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with extent of their participation in the activity.

Disclosure Statement

Policies and standards of MSSNY require that speakers and planners for CME activities disclose any relevant financial relationships they may have with commercial interests whose products, devices or services may be discussed in the content of a CME activity. 

  • Dr. James Braun (Planner/Course Director) had no relevant financial relationships to disclose.
  • Dr. Wyatt (Presenter) has no relevant financial relationships to disclose. Dr. Wyatt will support her presentation and clinical recommendations with the best available evidence from the medical literature, and will submit her slides in advance for adequate peer review.

Financial Support

This meeting of the Physicians’ Research Network (PRN) and enduring material were funded in part by educational grants from: Bristol-Myers Squibb, Gilead Sciences, Janssen Pharmaceuticals, Merck & Co, and ViiV Healthcare.

Details:

  • This online video and post-activity evaluation are one hour in length.
  • After you complete the video portion of this educational activity there will be a post-activity evaluation and quiz. 
  • You must achieve at least 70% correct to receive your CME certificate. 
  • If successful, you will be provided instructions to print your CME certificate at the completion of this activity.
PRN Learning Modules